Profound Medical (TSX:PRN) ROCE %: -47.66% (As of Mar. 2026)


TSX:PRN Profound Medical Corp TSX:PRN
68 GF Score
Price C$10.46
GF Value C$20.37
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Profound Medical ROCE %?

Profound Medical TSX:PRN +7.28% 68 ROCE % is -47.66% as of Mar. 2026. GuruFocus rates TSX:PRN with a GF Score™ of 68/100 and a GF Value™ of C$20.37 (Possible Value Trap). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Profound Medical's annualized ROCE % for the quarter that ended in Mar. 2026 was -47.66%.

Profound Medical  (TSX:PRN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Profound Medical ROCE % Related Terms

Profound Medical ROCE % Historical Data

* Premium members only.

The historical data trend for Profound Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Profound Medical ROCE % Chart

Profound Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -33.46 -40.86 -58.13 -66.75 -60.16

Profound Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -75.22 -107.96 -94.09 -56.76 -47.66
TSX:PRN
68GF Score
Profound Medical Corp TSX:PRN
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Profound Medical ROCE % Calculation

Profound Medical's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-56.91/( ( (100.062 - 9.353) + (106.877 - 8.38) )/ 2 )
=-56.91/( (90.709+98.497)/ 2 )
=-56.91/94.603
=-60.16 %

Profound Medical's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-44.02/( ( (106.877 - 8.38) + (100.782 - 14.553) )/ 2 )
=-44.02/( ( 98.497 + 86.229 )/ 2 )
=-44.02/92.363
=-47.66 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -47.66% mean?
Profound Medical (TSX:PRN) has a ROCE % of -47.66% as of Mar. 2026.
Is Profound Medical's ROCE % too high?
Profound Medical's current ROCE % is -47.66%. Overall, Profound Medical has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Profound Medical's ROCE % compare to ABT and SYK?
Profound Medical's ROCE % of -47.66% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.19. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.19, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profound Medical's current ROCE % is -47.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profound Medical stock overvalued right now?
Based on GuruFocus' analysis, Profound Medical (TSX:PRN) is currently considered Possible Value Trap. The stock's GF Value™ is C$20.37, compared to a current price of C$10.46 — trading 48.6% below its estimated fair value. The current ROCE % is -47.66%. Profound Medical's overall GF Score™ is 68/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Profound Medical (TSX:PRN), the current ROCE % is -47.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Profound Medical (TSX:PRN) Overvalued in 2026?

Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued. The current stock price of C$10.46 is trading 48.6% below its estimated GF Value™ of C$20.37. GuruFocus considers Profound Medical to be Possible Value Trap.

Key valuation signals for TSX:PRN:

  • ROCE %: -47.66%
  • GF Value™: C$20.37 vs. price of C$10.46 (48.6% below fair value)
  • GF Score™: 68/100 with 1 warning sign

No single metric tells the full story. See the TSX:PRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Profound Medical Business Description

Other Exchanges PROF:USA
Address 2400 Skymark Avenue, Unit 6, Mississauga, ON, CAN, L4W 5K5
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
68GF Score

Get the complete analysis for TSX:PRN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$10.46
Price
C$20.37
GF Value